The Technical Analyst
Rafael Holdings Inc [RFL]
Exchange: NYSE Sector: Real Estate Industry: Real Estate - Services
Rafael Holdings Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.29% $1.705
America/New_York / 26 apr 2024 @ 15:06
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 40.57 mill |
| EPS: | 0.100 |
| P/E: | 17.05 |
| Earnings Date: | Jun 11, 2024 |
| SharesOutstanding: | 23.80 mill |
| Avg Daily Volume: | 0.0236 mill |
| RATING 2024-04-26 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.56x |
| Company: PE 17.05 | sector: PE 30.55 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 17.05 | industry: PE -22.61 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.900 (-47.24%) $-0.805 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.643 - 1.777 ( +/- 3.92%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-04 | Jonas Howard S | Buy | 348 259 | Class B Common Stock, par value $.01 per share |
| 2024-04-04 | Jonas Howard S | Sell | 348 259 | Class B Common Stock, par value $.01 per share |
| 2024-03-21 | Conkling William | Buy | 15 473 | Class B Common Stock, par value $.01 per share |
| 2024-03-21 | Polinsky David | Sell | 2 300 | Class B Common Stock, par value $.01 per share |
| 2024-01-30 | Jonas Howard S | Buy | 348 259 | Class B Common Stock, par value $.01 per share |
| INSIDER POWER |
|---|
| 52.71 |
| Last 99 transactions |
| Buy: 18 593 840 | Sell: 14 829 947 |
Forecast:
16:00 - $1.705
Live Trading Signals (every 1 min)
Forecast
1: 15:16 - $1.714
Forecast 2: 16:00 - $1.705
Forecast 3: 16:00 - $1.705
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.705 (-0.29% ) |
| Volume | 0.0149 mill |
| Avg. Vol. | 0.0236 mill |
| % of Avg. Vol | 62.93 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RFL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
RFL
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Latest Press Releases
2024-03-13 17:04:00 - Press Release
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
Company remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments
2023-12-14 16:01:00 - Press Release
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments
2023-10-30 16:01:00 - Press Release
Rafael Holdings Reports Fourth Quarter And Full Year Fiscal 2023 Financial Results
Company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunities company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunities
2023-08-02 08:16:00 - Press Release
Cyclo Therapeutics Announces Closing Of $5.0 Million Private Placement With Rafael Holdings, Inc.
Gainesville, fla.--(business wire)--cyclo therapeutics, inc. (nasdaq: cyth) (“cyclo therapeutics” or the “company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has closed the previously announced private placement with rafael holdings, inc. (nyse:rfl) (“rafael”) for the purchase of 4,000,000 shares of common stock of cyclo therapeutics and warrants t.
2022-06-01 08:00:00 - Press Release
Cornerstone Pharmaceuticals To Present Pancreatic Cancer, Clear Cell Sarcoma And Biliary Tract Cancer Research Featuring Cpi-613® (devimistat) At The 2022 American Society Of Clinical Oncology (asco) Annual Meeting
Cranbury, nj, june 01, 2022 (globe newswire) -- cornerstone pharmaceuticals, inc. (“cornerstone” or the “company”), a company focused on rare cancer therapeutics and formerly known as rafael pharmaceuticals, today announced that the company and its partners will present three abstracts at the american society of clinical oncology (asco) annual meeting taking place june 3 – june 7, 2022 in chicago.
Latest News
2022-06-01 08:00:00 - GlobeNewsWire
Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Cranbury, NJ, June 01, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that the Company and its partners will present three abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3 – June 7, 2022 in Chicago.
2021-10-28 11:46:12 - The Motley Fool
Here's Why Rafael Holdings Is Plummeting Today
A clinical trial failure with the company's lead candidate has investors running for the exits.
2021-10-18 17:41:00 - Newsfile Corp
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation into the Fairness of the Merger of Rafael Holdings, Inc. with Rafael Pharmaceuticals, Inc.
New York, New York--(Newsfile Corp. - October 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Rafael Holdings, Inc. ("Rafael Holdings" or the "Company") (NYSE: RFL) stock prior to August 16, 2021.You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of Rafael Holdings with Rafael Pharmaceuticals, Inc. U
2021-10-18 17:30:00 - GlobeNewsWire
Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08
NEWARK, N.J., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), announced that today it made a grant to Dr. Mary Margaret Huizinga of options to purchase 122,341 shares of Class B common stock of the Company with an exercise price equal to $30.54, the closing price of the Class B common stock on October 15, 2021, the trading day prior to the grant.
2021-10-18 16:30:00 - GlobeNewsWire
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2021 Financial and Operating Results and Provides Business Update
We expect Rafael Pharmaceuticals to report top line data from its AVENGER 500 Phase 3 registrational clinical trial in metastatic pancreatic cancer this calendar year
2021-10-06 06:30:00 - PRNewsWire
Rafael Holdings Appoints Mimi Huizinga, MD, MPH as Chief Development and Medical Officer
NEWARK, N.J., Oct. 6, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute and investment in Rafael Pharmaceuticals, Inc., announced today the appointment of Mary Margaret (Mimi) Huizinga, MD, MPH as Chief Development and Medical Officer, effective October 18, 2021.
2021-09-27 08:00:00 - GlobeNewsWire
Rafael Pharmaceuticals Announces APOLLO613 Phase I/II Clinical Trial of CPI-613® (devimistat) in Combination with Hydroxychloroquine in Patients with Relapsed Clear Cell Sarcoma Begins Enrollment at City of Hope in Duarte, Calif.
CRANBURY, N.J., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced that the Phase 1 clinical trial of CPI-613® (devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma is open for enrollment. The clinical trial will begin enrolling patients at City of Hope in Duarte, California, with other sites across the country to quickly follow.
2021-09-24 16:30:00 - PRNewsWire
Rafael Holdings Continues to Expand its Management Team with a Highly Experienced Global Biopharmaceutical Executive to Build a Fully Integrated Cancer Metabolism Therapeutics Company and Announces Inducement Grant Under NYSE Rule 303A.08
NEWARK, N.J., Sept. 24, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute and investment in Rafael Pharmaceuticals, Inc., announced today the appointment of Ashok Marin, Chief Legal Officer.
2021-09-17 16:01:00 - PRNewsWire
Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08
NEWARK, N.J., Sept. 17, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute and investment in Rafael Pharmaceuticals, Inc., announced today it made a grant to Patrick Fabbio of options to purchase 105,602 shares of Class B common stock of the Company with an exercise price equal to $36.32, the closing price of the Class B common stock on September 16, 2021, the trading day prior to the grant.
2021-09-14 08:27:00 - PRNewsWire
Rafael Holdings Appoints Patrick Fabbio as Chief Financial Officer
NEWARK, N.J., Sept. 14, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute and investment in Rafael Pharmaceuticals, Inc., announced today the appointment of Patrick Fabbio as Chief Financial Officer.